DiaMedica's Pivotal Stroke Trial Reaches 75% Enrollment, Signaling Progress After Prior Delays
DMAC sits 60% above its 52-week low of $3.475.
Summary
DiaMedica Therapeutics announced a significant operational milestone, achieving 75% enrollment in its pivotal ReMEDy2 Phase 2/3 acute ischemic stroke trial. This update is particularly material given that the company's recent Q1 10-Q filing on May 6, 2026, specifically cited "significant delays and challenges" in this trial. Reaching this advanced stage of enrollment suggests the company is effectively addressing those prior issues, which is a positive de-risking event for a clinical-stage biotech. This progress indicates a clearer path towards trial completion and eventual data readout, which will be the next major catalyst for the stock.
At the time of this announcement, DMAC was trading at $5.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.1M. The 52-week trading range was $3.48 to $10.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.